Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SHERISE DESIREE FERGUSON and AMY B HEIMBERGER.
SHERISE DESIREE FERGUSON
Connection Strength
5.842
AMY B HEIMBERGER
  1. A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdaa146.
    View in: PubMed
    Score: 0.754
  2. Profiles of brain metastases: Prioritization of therapeutic targets. Int J Cancer. 2018 12 01; 143(11):3019-3026.
    View in: PubMed
    Score: 0.654
  3. Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas. J Neuropathol Exp Neurol. 2018 06 01; 77(6):437-442.
    View in: PubMed
    Score: 0.638
  4. Ependymomas overexpress chemoresistance and DNA repair-related proteins. Oncotarget. 2018 Jan 30; 9(8):7822-7831.
    View in: PubMed
    Score: 0.618
  5. GBM-associated mutations and altered protein expression are more common in young patients. Oncotarget. 2016 Oct 25; 7(43):69466-69478.
    View in: PubMed
    Score: 0.571
  6. Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope? Immunotherapy. 2016; 8(4):413-23.
    View in: PubMed
    Score: 0.540
  7. The role of STAT3 in tumor-mediated immune suppression. J Neurooncol. 2015 Jul; 123(3):385-94.
    View in: PubMed
    Score: 0.508
  8. CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease. Front Immunol. 2021; 12:745893.
    View in: PubMed
    Score: 0.201
  9. Targeting the Tumor Microenvironment in Brain Metastasis. Neurosurg Clin N Am. 2020 Oct; 31(4):641-649.
    View in: PubMed
    Score: 0.187
  10. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.
    View in: PubMed
    Score: 0.182
  11. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J Neurooncol. 2019 May; 142(3):499-509.
    View in: PubMed
    Score: 0.168
  12. Tumor Vaccines for Malignant Gliomas. Neurotherapeutics. 2017 04; 14(2):345-357.
    View in: PubMed
    Score: 0.147
  13. Immunotherapy in glioblastoma: emerging options in precision medicine. CNS Oncol. 2016 07; 5(3):175-86.
    View in: PubMed
    Score: 0.139
  14. Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology. 2016 Jun; 5(6):e1145332.
    View in: PubMed
    Score: 0.136
  15. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res. 2013 Jul 01; 73(13):3913-26.
    View in: PubMed
    Score: 0.112
  16. The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. Oncotarget. 2012 Mar; 3(3):336-44.
    View in: PubMed
    Score: 0.103
  17. Response of treatment-naive brain metastases to stereotactic radiosurgery. Nat Commun. 2024 May 02; 15(1):3728.
    View in: PubMed
    Score: 0.060
  18. Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression. JCI Insight. 2022 05 09; 7(9).
    View in: PubMed
    Score: 0.052
  19. Perilesional Resection of Glioblastoma Is Independently Associated With Improved Outcomes. Neurosurgery. 2020 01 01; 86(1):112-121.
    View in: PubMed
    Score: 0.044
  20. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol. 2012 Sep; 14(9):1136-45.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.